The Bright Pink PROACT Program at Stanford Medicine
In 2024, Bright Pink made a $3.5 million legacy gift to establish the Bright Pink Preventive Risk Outreach And Cascade Testing (PROACT) Program at Stanford Medicine. Led by Stanford physicians Dr. Allison Kurian and Dr. Jennifer Caswell-Jin, in collaboration with the University of Michigan, the Bright Pink PROACT Program aims to democratize access to cascade testing. This type of genetic testing, which identifies hereditary mutations like BRCA1 and BRCA2 and extends testing to family members, holds enormous potential to save lives from breast and ovarian cancer, yet remains significantly underutilized, with only one-third of those at risk taking action.
The Bright Pink PROACT Program aims to change this. The platform, tested through Stanford’s GIFT Trial, has already significantly increased cascade testing participation rates by enabling mutation carriers to facilitate genetic testing for their relatives. By making sharing family health information—and acting on it—easier, faster, and more accessible than ever, the program intends to empower families nationwide to understand and share their genetic risks, enabling their loved ones to take life-saving preventive action.
From Bright Pink's first 15 years serving millions of women with life-saving education and resources to its recent work advancing health equity through the Bright Pink Venture Fund, its mission has remained the same: to save young women's lives from breast and ovarian cancer through bold, innovative solutions. The Bright Pink PROACT Program will carry this legacy forward, shaping a better, brighter future for generations to come.
Bright Pink Founder Lindsay Avner Kaplan is proud to serve as a Senior Advisor to the Bright Pink PROACT Program at Stanford Medicine, leveraging her extensive experience in supporting and engaging women at risk to ensure the program’s resources are both impactful and accessible.